Cerevel Therapeutics Holdings Stock Investor Sentiment

CERE Stock  USD 42.30  0.24  0.57%   
About 60% of Cerevel Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Cerevel Therapeutics Holdings suggests that many traders are alarmed. Cerevel Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Cerevel Therapeutics Holdings. The current market sentiment, together with Cerevel Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Cerevel Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

40

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Cerevel Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Cerevel Therapeutics Holdings.
Cerevel Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Cerevel daily returns and investor perception about the current price of Cerevel Therapeutics Holdings as well as its diversification or hedging effects on your existing portfolios.

Cerevel Historical Sentiment

Although Cerevel Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Cerevel, such as negative comments on social media and news outlets, may cause fear in the market and push Cerevel Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Cerevel.
  

Cerevel Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Cerevel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Cerevel Therapeutics Maximum Pain Price across 2024-05-17 Option Contracts

Cerevel Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Cerevel Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Cerevel Therapeutics' options.
over three months ago at gizmodo.com         
The Fictional Characters We Lost in 2023
news
over three months ago at news.google.com         
Cerevel Therapeutics Holdings, Inc. Short Interest Update - MarketBeat
Google News at Macroaxis
over three months ago at prnewswire.com         
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates CERE, IMGN, ROVR, GRPH
prnewswire News
over three months ago at thelincolnianonline.com         
Brokerages Set Cerevel Therapeutics Holdings, Inc. Target Price at 32.33
news
over three months ago at thelincolnianonline.com         
Exercise or conversion by Sanchez Ramiro of 10000 shares of Cerevel Therapeutics subject to Rule 16b...
news
over three months ago at thelincolnianonline.com         
Cerevel Therapeutics Rating Reiterated by TD Cowen
news
over three months ago at thelincolnianonline.com         
Cerevel Therapeutics Downgraded by HC Wainwright
news
over three months ago at thelincolnianonline.com         
Insider Selling Cerevel Therapeutics Holdings, Inc. Insider Sells 413,700.00 in Stock
news
over three months ago at prnewswire.com         
ALERT Juan Monteverde Encourages the Shareholders of CERE, PFIN, NWLI, CSTR to Take Action
prnewswire News
over three months ago at thelincolnianonline.com         
Cerevel Therapeutics Receives Neutral Rating from Piper Sandler
news
over three months ago at marketwatch.com         
Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup
marketwatch News
over three months ago at seekingalpha.com         
AbbVie Cerevel deal followed unusual options trading
seekingalpha News
over three months ago at thelincolnianonline.com         
Cerevel Therapeutics Neutral Rating Reaffirmed at Cantor Fitzgerald
news
over three months ago at businesswire.com         
CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC...
businesswire News
over three months ago at fool.com         
AbbVies on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
fool News
Far too much social signal, news, headlines, and media speculation about Cerevel Therapeutics that are available to investors today. That information is available publicly through Cerevel media outlets and privately through word of mouth or via Cerevel internal channels. However, regardless of the origin, that massive amount of Cerevel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cerevel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cerevel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cerevel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cerevel Therapeutics alpha.

Cerevel Therapeutics Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
Cerevel Therapeutics Sees Large Volume Increase
02/22/2024
2
Disposition of 50000 shares by Coles N Anthony of Cerevel Therapeutics at 41.011 subject to Rule 16b-3
03/04/2024
3
Jefferies likes these dividend-growing stocks for 2024
03/18/2024
4
Disposition of 10000 shares by Sanchez Ramiro of Cerevel Therapeutics at 3.5 subject to Rule 16b-3
03/27/2024
5
Disposition of 50000 shares by Coles N Anthony of Cerevel Therapeutics at 42.3328 subject to Rule 16b-3
04/01/2024
6
Cerevel Therapeutics director sells 2.12m in stock, buys 175k worth
04/03/2024
7
International Assets Investment Management LLC Acquires Shares of 55120 Cerevel Therapeutics Holdings, Inc ... - Defense World
04/11/2024
8
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
04/15/2024
9
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinsons Disease
04/18/2024
10
Roundup Pitman keeps CCAL baseball playoff race close with walk-off win over Gregori
04/25/2024
11
AbbVie Reports First-Quarter 2024 Financial Results
04/26/2024
12
The top pharmaceutical companies by RD expenditure
05/02/2024
13
How Neurocrine, An IBD 50 Stock, Is Stacking Up Wins In 2024 And Outperforming Peers
05/09/2024
When determining whether Cerevel Therapeutics is a strong investment it is important to analyze Cerevel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cerevel Therapeutics' future performance. For an informed investment choice regarding Cerevel Stock, refer to the following important reports:

Complementary Tools for Cerevel Stock analysis

When running Cerevel Therapeutics' price analysis, check to measure Cerevel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerevel Therapeutics is operating at the current time. Most of Cerevel Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cerevel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerevel Therapeutics' price. Additionally, you may evaluate how the addition of Cerevel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Is Cerevel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cerevel Therapeutics. If investors know Cerevel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cerevel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.73)
Return On Assets
(0.30)
Return On Equity
(0.92)
The market value of Cerevel Therapeutics is measured differently than its book value, which is the value of Cerevel that is recorded on the company's balance sheet. Investors also form their own opinion of Cerevel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cerevel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cerevel Therapeutics' market value can be influenced by many factors that don't directly affect Cerevel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cerevel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cerevel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cerevel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.